Direkt zum Inhalt
Merck
  • Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis.

Methamphetamine accelerates cellular senescence through stimulation of de novo ceramide biosynthesis.

PloS one (2015-02-12)
Giuseppe Astarita, Agnesa Avanesian, Benedetto Grimaldi, Natalia Realini, Zuzana Justinova, Leight V Panlilio, Abdul Basit, Steven R Goldberg, Daniele Piomelli
ZUSAMMENFASSUNG

Methamphetamine is a highly addictive psychostimulant that causes profound damage to the brain and other body organs. Post mortem studies of human tissues have linked the use of this drug to diseases associated with aging, such as coronary atherosclerosis and pulmonary fibrosis, but the molecular mechanism underlying these findings remains unknown. Here we used functional lipidomics and transcriptomics experiments to study abnormalities in lipid metabolism in select regions of the brain and, to a greater extent, peripheral organs and tissues of rats that self-administered methamphetamine. Experiments in various cellular models (primary mouse fibroblasts and myotubes) allowed us to investigate the molecular mechanisms of systemic inflammation and cellular aging related to methamphetamine abuse. We report now that methamphetamine accelerates cellular senescence and activates transcription of genes involved in cell-cycle control and inflammation by stimulating production of the sphingolipid messenger ceramide. This pathogenic cascade is triggered by reactive oxygen species, likely generated through methamphetamine metabolism via cytochrome P450, and involves the recruitment of nuclear factor-κB (NF-κB) to induce expression of enzymes in the de novo pathway of ceramide biosynthesis. Inhibitors of NF-κB signaling and ceramide formation prevent methamphetamine-induced senescence and systemic inflammation in rats self-administering the drug, attenuating their health deterioration. The results suggest new therapeutic strategies to reduce the adverse consequences of methamphetamine abuse and improve effectiveness of abstinence treatments.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Fumonisin B1 aus Fusarium moniliforme, ≥98% (HPLC)
Sigma-Aldrich
Clotrimazol
Supelco
Clotrimazol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Myriocin aus Mycelia sterilia, ≥98% (HPLC), powder
Sigma-Aldrich
Chinidin, anhydrous
Sigma-Aldrich
Chinidin, crystallized, ≥98.0% (dried material, NT)
Sigma-Aldrich
(±)-Thalidomid, ≥98%, powder
USP
Clotrimazol, United States Pharmacopeia (USP) Reference Standard
USP
Cefazolin, United States Pharmacopeia (USP) Reference Standard
Supelco
Fumonisin B1 -Lösung, ~50 μg/mL in acetonitrile: water, analytical standard
Sigma-Aldrich
L-Cycloserin
Supelco
Fumonisin B1, reference material, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Clotrimazol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Clotrimazol, European Pharmacopoeia (EP) Reference Standard
Cefazolin, European Pharmacopoeia (EP) Reference Standard
Supelco
Proadifen -hydrochlorid, analytical standard, ≥95%